Founded in 1999, the Company is focusing on the unmet needs of healthcare and life science industry. Aviva has pioneered cell-based platforms, which have led to an innovative product (SealChip™) which has become the industry standard for ion channel-focused drug discovery. The Company continues to leverage its expertise in cell-based assays by targeting new commercial applications which will benefit patients. Aviva is currently developing innovative rare cell enrichment technologies, particularly focused on circulating tumor cells (CTC), which will significantly advance the accuracy and sensitivity of cancer disease diagnosis and monitoring.
Based in San Diego, CA., AVIVA Biosciences Corporation develops enabling drug discovery and development technologies by combining biochips with cell biology. Key application areas include electrophysiology research, ion channel drug screening and rare-cell isolation.
Siyu Chen, Ph.D.
In this interview, we discuss a new approach to surface-enhanced Raman spectroscopy that utilizes nano-pockets to capture target molecules, ensuring a highly sensitive way to detect chemical processes.
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
This article outlines how Unity, Oxford Instruments’ new detector for a revolutionary new imaging technique, can be used to revolutionize imaging.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.